Shares of Travere Therapeutics Inc. (TVTX) were up over 8% at $10.25 in after-hours trading Thursday, following favorable regulatory news.
The FDA has granted full approval to Filspari to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.